Conference Reports for NATAP

Back

Conference on Retroviruses and Opportunistic Infections Will be Virtual Boston USA March 6-10, 2021     CROI: 28th Virtual Conference on Retroviruses and Opportunistic Infection March 7-10, 2021 Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center - (04/27/21)   CROI 2021 Highlights By Christina K. Psomas, M.D. European Hospital Marseille, Marseille, France - (04/26/21)   Clinical Pharmacology at CROI 2021. New Drugs & Formulations; PrEP; HIV Treatment - Courtney V. Fletcher, Pharm.D. Professor UNMC Center for Drug Discovery University of Nebraska Medical Center 986000 Nebraska Medical Center - (04/21/21)   Summary from virtual CROI 2021 for HIV and liver disease HIV and the liver: hot topics - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (04/10/21)   HIV Prevention at CROI 2021. NATAP Report by Renee Heffron, PhD and Connie Celum, MD, University of Washington - (04/13/21)   CANNABIS USE ASSOCIATED WITH DECREASED ART ADHERENCE IN AGING PEOPLE WITH HIV - (05/10/21)   FEMINIZING THERAPY DECREASES D-DIMER BUT WORSENS INSULIN SENSITIVITY IN TRANS WOMEN - (05/08/21)   LOWER UPTAKE OF DOLUTEGRAVIR AMONG WOMEN OF REPRODUCTIVE POTENTIAL VS MEN-KENYA - (04/14/21)   DRAMATIC DECLINE IN PUBLIC SECTOR HIV/STI TESTING DURING SARS-CoV-2 PANDEMIC, OREGON - (04/13/21)   SERUM BIOMARKERS IDENTIFY CARDIAC DYSFUNCTION IN (perinatally infected) YOUTH LIVING WITH HIV - (04/06/21)   QUINOLINIC ACID IS ASSOCIATED WITH CAROTID INTIMA-MEDIA THICKNESS IN HIV - (04/06/21)   DORAVIRINE CONCENTRATIONS AND HIV-1 RNA SUPPRESSION IN MALE AND FEMALE GENITAL FLUIDS - (04/06/21)   TRENDS IN TRUVADA AND DESCOVY PRESCRIPTIONS FOR PrEP IN THE UNITED STATES, 2014-2020 - (04/05/21)   TOTAL AND UNBOUND DORAVIRINE CONCENTRATIONS AND VIRAL SUPPRESSION IN CSF OF HIV+ PTS - (04/05/21)   VIRUS REMISSION WITH AN OPTIMIZED EARLY ART REGIMEN IN MACAQUES - (04/05/21)   IMPAACT 2014 24-WEEK PK AND SAFETY OF DORAVIRINE/3TC/TDF IN ADOLESCENTS WITH HIV-1 - (04/05/21)   REMDESIVIR VERSUS STANDARD OF CARE FOR SEVERE COVID-19 - (04/05/21)   ACUTE KIDNEY INJURY IN PATIENTS WITH MODERATE COVID-19 TREATED WITH RDV VERSUS SoC - (04/05/21)   TREATMENT AND OUTCOMES OF COVID-19 IN THE US: ARE THEY DIFFERENT ACCORDING TO RACE? - (04/05/21)   SAFETY AND EFFICACY OF REMDESIVIR IN A PEDIATRIC COVID-19 POPULATION - (04/05/21)   VASCULAR INJURY MARKERS ASSOCIATED WITH COGNITIVE IMPAIRMENT IN HIV PATIENTS ON ART - (03/30/21)   SEX DIFFERENCES IN WHITE-MATTER LOSS AND ASSOCIATED AXONAL INJURY IN PLWH - (03/30/21)   RELATIONSHIP OF T-CELL MITOCHONDRIAL GENE EXPRESSION AND DIABETES IN PERSONS WITH HIV - (03/28/21)   ELUCIDATING THE ORIGINS OF HIV-1 IN THE CEREBROSPINAL FLUID - (03/28/21)   CORONARY ARTERY DISEASE, TRADITIONAL RISK, AND INFLAMMATION AMONG PWH IN REPRIEVE - (03/28/21)   Women & HIV at CROI - (03/28/21)   Neurocognition & PLWH - CROI 2021 - (03/28/21)   Laboratory Analysis of HIV Infections in HPTN 083: Injectable CAB for PrEP - (03/26/21)   HIV AMBULATORY CARE DURING COVID-19 PANDEMIC IN US: VISITS AND VIRAL LOAD TESTING - "dropped precipitously" - (03/20/21)   IMPACT OF COVID-19 ON COMMERCIAL LABORATORY TESTING FOR HIV IN THE UNITED STATES - (03/22/21)   COVID & HIV - Antiviral Molnupiravir, monoclonal antibody combinations, Convalesecent Plasma - (03/19/21)   Weight Gain / Loss - (03/19/21)   New PrEP at CROI 2021 - (03/19/21)   CROI 2021 - Complications: HIV, COVID - (03/19/21)   CROI 2021 - New HIV Drugs - (03/19/21)   Aging & HIV Highlights at CROI 2021 - (03/24/21)   STATIN USE AND COGNITIVE PERFORMANCE IN THE MULTICENTER AIDS COHORT STUDY - (03/26/21)   DECREASED HIV DIAGNOSES AMONG MSM OF COLOR IN THRIVE-FUNDED JURISDICTIONS, 2014-2018 - (03/25/21)   GENDER-AFFIRMING SURGERY ASSOCIATED WITH HIGH VIRAL SUPPRESSION AMONG TRANSGENDER PWH - (03/25/21)   IMPACT OF COMMON SIDE EFFECTS ON PrEP PERSISTENCE DURING PREGNANCY IN SOUTH AFRICA - (03/25/21)   FREQUENT HBsAg CLEARANCE DURING TENOFOVIR THERAPY IN HIV/ HBV COINFECTION - (03/25/21)   PHARMACY REVERSALS: A NOVEL INDICATOR OF GAPS IN THE HIV PrEP CARE CASCADE - (03/21/21)   A NOVEL APPROACH TO MEASURE PrEP UPTAKE AMONG POPULATIONS WITH PERSISTENT HIV RISK - (03/21/21)   IMMUNE MARKERS AND TO TIME TO REBOUND DURING HIV TREATMENT INTERRUPTION IN ACTG A5345 - (03/21/21)   EPIGENETIC AGING ASSOCIATED WITH COGNITIVE IMPAIRMENT IN OLDER BLACK ADULTS WITH HIV - (03/24/21)   DEMENTIA INCIDENCE AMONG ART-TREATED PEOPLE WITH HIV IN A PRIMARY CARE SETTING - (03/24/21)   NEUROCOGNITIVE DYSFUNCTION, INFLAMMATION, AND ADIPOSITY IN TREATED HIV PATIENTS - (03/24/21)   PWH AND ALZHEIMER'S DISEASE RISK: CLARIFYING THE HAND PHENOTYPE OVER TIME - (03/24/21)   HEPATITIS B SEROPROTECTION AMONG YOUNG ADULTS LIVING WITH PERINATALLY ACQUIRED HIV - (03/23/21)   A SIMPLE AND SAFE APPROACH TO HCV TREATMENT: FINDINGS FROM THE A5360 (MINMON) TRIAL - (03/23/21)   BARRIERS IMPACTING TELEHEALTH MEDICAL-APPOINTMENT ADHERENCE AMONG PLWHA - (03/23/21)   PrEP USE AND REFERRAL: BLACK PARTNERS OF PEOPLE WITH HIV IN PARTNER SERVICES, 2019 - (03/22/21)   A SURVEY-BASED PILOT STUDY TO ASSESS THE EFFECTS OF COVID-19 ISOLATION ON OLDER PLWH - (03/22/21)   LOW PROPORTIONS OF LINKAGE & PRESCRIPTIONS OF PrEP IN BLACK WOMEN (THRIVE, 2015-2020) - (03/22/21)   CHANGES IN ACCESS TO CARE FOR WOMEN LIVING WITH HIV DURING THE COVID-19 PANDEMIC - (03/22/21)   PLWH AND CANCER EXHIBIT UNIQUE PATTERN OF ACTIVATED AND EXHAUSTED CD8+ T CELLS - (03/22/21)   RANDOMIZED CONTROLLED TRIAL OF MARAVIROC FOR HIV-ASSOCIATED NEUROCOGNITIVE IMPAIRMENT - (03/22/21)   THE USE OF LESS NEUROTOXIC ANTIRETROVIRALS: SECONDARY ENDPOINTS OF THE MARAND-X STUDY - (03/22/21)   IMMUNE MARKERS AND TO TIME TO REBOUND DURING HIV TREATMENT INTERRUPTION IN ACTG A5345 - (03/22/21)   PREDICTORS OF PrEP UPTAKE IN A SEXUAL HEALTH CLINIC WITH IMMEDIATE PrEP INITIATION - (03/20/21)   RISK OF CANCER BY HIV STATUS AND BIRTH REGION: A NATIONWIDE REGISTER-BASED STUDY - (03/20/21)   ACTIVATING PKC-ε INDUCES HIV EXPRESSION WITH IMPROVED TOLERABILITY - (03/20/21)   HIV REBOUND IN CONTROLLERS IS ASSOCIATED WITH SPECIFIC FECAL MICROBIOME PROFILE - (03/20/21)   MATHEMATICAL MODELING OF PREDICTORS OF POSTTREATMENT CONTROL IN HIV CURE TRIALS - (03/20/21)   EVALUATION OF bNAb SENSITIVITY BY GENOTYPING AND PHENOTYPING FOR HIV CLINICAL TRIALS - (03/19/21)   ULTRASENSITIVE HIV-1 DRUG-RESISTANCE ANALYSIS IN THE DISCOVER PrEP TRIAL - (03/19/21)   THE ANTIRETOVIRAL PREGNANCY REGISTRY: 30 YEARS OF MONITORING FOR CONGENITAL ANOMALIES - (03/19/21)   SEX DIFFERENCES IN DIABETES PREVELANCE AMONG PERSONS WITH HIV IN THE UNITED STATES...40% of HIV+ Women >65 have diabetes. - (03/19/21)   IMPACT OF REPRODUCTIVE AGING ON HIV PERSISTENCE IN CISGENDER MEN AND WOMEN WITH HIV - (03/19/21)   ACCELERATED CEREBRAL BLOOD-FLOW REDUCTION AND BRAIN AGING IN PEOPLE LIVING WITH HIV PLWH associated with accelerated brain age - (03/17/21)   INCIDENT DIABETES ASSOCIATED WITH INTEGRASE STRAND TRANSFER INHIBITOR INITIATION - (03/17/21)   CSF MARKERS OF AD-RELATED PATHOLOGY AND MEMORY DEFICITS IN OLDER PEOPLE WITH HIV - (03/17/21)   Incidence of HIV infection with daily or on-demand oral PrEP with TDF/FTC in France - (03/17/21)   NEURON DAMAGE AND RESERVOIR ARE SECONDARY TO HIV TRANSCRIPTS DESPITE SUPPRESSIVE ART - (03/17/21)   DRUG-USE STIGMA AND HEPATITIS C VIRUS INFECTION AMONG PWID IN INDIA - (03/17/21)   ACCESS TO HCV CARE AMONG HIV/HCV-COINFECTED PEOPLE WHO INJECT DRUGS ACROSS CANADA - (03/16/21)   HIV/HCV COINFECTION TRENDS IN SPAIN (2015-2019) - (03/16/21)   NO CHANGE IN INCIDENCE OF RECENTLY ACQUIRED HCV IN HIV+ MSM IN GERMANY (NOCO COHORT) - (03/16/21)   HEPATITIS C CASCADE OF CARE IN HIV/HCV-COINFECTED PERSONS IN EUROPE IN THE DAA ERA - (03/16/21)   SELF-TESTING FOR HCV: MULTICOUNTRY EVIDENCE ON USABILITY AND ACCEPTABILITY - (03/16/21)   COST-EFFECTIVENESS OF HCV TESTING STRATEGIES FOR HCV ELIMINATION AMONG MSM IN THE US - (03/16/21)   REINFECTION WITH THE HEPATITIS C VIRUS IN MEN WHO HAVE SEX WITH MEN - (03/16/21)   PREVALENCE AND FACTORS ASSOCIATED WITH SARS-CoV-2 ANTIBODIES IN A SPANISH HIV COHORT - (03/16/21)   COVID-19 IN HOSPITALIZED HIV-POSITIVE AND HIV-NEGATIVE PATIENTS: A MATCHED STUDY - (03/16/21)   SECOND ANTIRETROVIRAL THERAPY REGIMEN IN VIREMIC PEOPLE WITH HIV IN THE US, 2008-2018 - (03/15/21)   CHARACTERIZING FIRST VIRAL FAILURES AMONG ANTIRETROVIRAL THERAPY INITIATORS IN THE US - (03/15/21)   Dual mAb Prevents Symptomatic COVID-19 in Household-Exposed Group: Interim Results of Placebo-Controlled Trial - Mark Mascolini (03/15/21)   RISK FACTORS FOR HOSPITALIZATION IN PEOPLE WITH HIV AND COVID-19 - (03/15/21)   T-CELL IMMUNE DYSREGULATION AND MORTALITY IN WOMEN WITH HIV - (03/15/21)   Risk factors for progression from prediabetes to diabetes in persons with HIV - Integrase Inhibitors Tied to Lower Risk of Progression from Prediabetes to Diabetes - HAILO - Mark Mascolini - (03/15/21)   PREDICTED 10-YEAR RISKS OF CARDIOVASCULAR DISEASE AND DIABETES IN THE ADVANCE TRIAL - (03/15/21)   CARDIOMETABOLIC HEALTH IN HIV+ AND HIV- PREGNANT SOUTH AFRICAN WOMEN - (03/15/21)   CASIRIVIMAB WITH IMDEVIMAB ANTIBODY COCKTAIL FOR COVID-19 PREVENTION: INTERIM RESULTS - (03/15/21)   PREDICTED LONG-TERM ADVERSE BIRTH AND CHILD HEALTH OUTCOMES IN THE ADVANCE TRIAL - (03/15/21)   In US Groups COVID Testing More Likely With HIV, But Positivity Similar With/Without HIV - Mark Mascolini (03/15/21)   HIV-1 DNA GENOTYPING IS OFTEN VARIABLE IN REPEAT TESTING FROM SINGLE BLOOD DRAWS - (03/15/21)   URINE MITOCHONDRIAL DNA, WEIGHT LOSS, AND BODY COMPOSITION IN OLDER ADULTS WITH HIV - (03/14/21)   COMORBIDITY BURDEN IS ASSOCIATED WITH HOSPITALIZATION FOR COVID-19 AMONG PWH - (03/14/21)   CHARACTERIZING COVID-19 PRESENTATION AND CLINICAL OUTCOMES IN HIV PATIENTS IN THE US - (03/14/21)   Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir - (03/14/21)   Online Mindfulness Lessons Ease Depression, Anxiety in Older HIV+ During COVID - Mark Mascolini (03/14/21)   IN VITRO MODEL TO ASSESS ANTIRETROVIRAL THERAPY ON ADIPOCYTE BIOLOGY - (03/14/21)   BEYOND PAIN: PRESCRIPTION OPIOID USE IN THE WOMEN'S INTERAGENCY HIV STUDY - (03/14/21)   ASSOCIATION BETWEEN INTEGRASE INHIBITORS (InSTIs) AND CARDIOVASCULAR DISEASE (CVD) - (03/14/21)   INFLAMMATORY AND ATHEROGENESIS MARKERS 148 WEEKS POSTSWITCH TO DTG+RPV IN SWORD-1/ -2 - (03/14/21)   RENAL/BONE OUTCOMES AFTER LONG-ACTING CABOTEGRAVIR + RILPIVIRINE IN ATLAS + ATLAS-2M - (03/14/21)   WEIGHT GAIN POST-ART IN HIV+ LATINOS/AS DIFFERS IN THE US, CANADA, AND LATIN AMERICA - (03/14/21)   CHARACTERISTICS OF HIV+ AND HIV- PATIENTS UNDERGOING BARIATRIC SURGERY: OBEVIH STUDY - (03/14/21)   HEROIN USE IS ASSOCIATED WITH HIGH-AORTIC BUT LOW-SPLEEN/ MARROW UPTAKE BY PET IN HIV - (03/14/21)   HIV Linked to 4.5-Fold Higher Risk of Aortic Aneurysm - Mark Mascolini (03/14/21)   BEYOND PAIN: PRESCRIPTION OPIOID USE IN THE WOMEN'S INTERAGENCY HIV STUDY - (03/12/21)   Acute Kidney Injury Less Frequent With Remdesivir Than Standard of Care - Mark Mascolini (03/12/21)   HIV REPLICATION IN THE CNS IS ASSOCIATED WITH NEUROCOGNITION AND DEPRESSION PRE-ART - (03/12/21)   FACTORS ASSOCIATED WITH SYSTEMIC IMMUNE ACTIVATION IN A GLOBAL HIV COHORT - (03/12/21)   INTRANASAL INSULIN IMPROVES ATTENTION AND MEMORY IN PEOPLE WITH HIV - (03/12/21)   HIV-1, INSUFFICIENT SLEEP, AND ENDOTHELIAL VASODILATOR FUNCTION - (03/12/21)   FTC-TP in Dried Blood Spots Predicts Future Detectable Viral Load in US Study - Mark Mascolini (03/12/21)   Resistance and Response in Phase 2a Study of HIV Maturation Inhibitor - Mark Mascolini (03/12/21)   Favipiravir Has Clinical Pluses vs Standard Care for In-Hospital COVID-19 - Mark Mascolini (03/12/21)   A PLACEBO-CONTROLLED ATI TRIAL OF HTI VACCINES IN EARLY TREATED HIV INFECTION - (03/12/21)   DIET QUALITY BY GLOBAL BURDEN OF DISEASE REGION IN PWH IN THE REPRIEVE TRIAL - (03/12/21)   MATERNAL WEIGHT AND ADVERSE PREGNANCY OUTCOMES AMONG WOMEN ON ART AT CONCEPTION - (03/11/21)   ANTEPARTUM WEIGHT GAIN AND ADVERSE PREGNANCY OUTCOMES IN IMPAACT 2010 - (03/11/21)   SAFETY/EFFICACY OF DTG VS EFV, TDF VS TAF IN PREGNANCY/POSTPARTUM: IMPAACT 2010 TRIAL - (03/11/21)   Complex Vaccine-Escape Mutation Profiles in 947 People With HBV - (03/11/21)   Complex Vaccine-Escape Mutation Profiles in 947 People With HBV - Mark Mascolini - (03/11/21)   PHASE 1 PK, SAFETY, AND ACCEPTABILITY STUDY OF 3-MONTH DAPIVIRINE VAGINAL RINGS - (03/11/21)   RCT OF AN ONLINE MENTAL HEALTH INTERVENTION AMONG OLDER PLWH DURING COVID-19 PANDEMIC - Improved Depression, Anxiety & Loneliness - (03/11/21)   HIGHER COMORBIDITY BURDEN PREDICTS WORSENING NEUROCOGNITION IN PEOPLE WITH HIV - (03/11/21)   New PrEP at CROI 2021 - (03/11/21)   WEEK 96 EFFICACY AND SAFETY OF CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS: ATLAS-2M - (03/11/21)   Three-Month Vaginal Ring Yields Higher Dapivirine Levels in US Study - Mark Mascolini (03/10/21)   Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021 - (03/10/21)   ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV - (03/10/21)   DOLUTEGRAVIR-BASED ART IS SUPERIOR TO NNRTI/PI-BASED ART IN CHILDREN AND ADOLESCENTS - (03/10/21)   BAMLANIVIMAB+ETESEVIMAB FOR TREATMENT OF COVID-19 IN HIGH- RISK AMBULATORY PATIENTS - (03/10/21)   Convalescent Plasma Has No Effect on Survival or Disease Course With Severe COVID-19 - Mark Mascolini (03/10/21)   mAb Bamlanivimab Lowers Odds of SARS-CoV-2 and Symptomatic COVID-19 in Nursing Facilities - Mark Mascolini - (03/10/21)   BAMLANIVIMAB PREVENTS COVID-19 MORBIDITY AND MORTALITY IN NURSING-HOME SETTING - (03/10/21)   REDUCTION IN INFECTIOUS SARS-CoV-2 IN TREATMENT STUDY OF COVID-19 WITH MOLNUPIRAVIR - (03/10/21)   DoLPHIN2 FINAL RESULTS DOLUTEGRAVIR VS EFAVIRENZ IN LATE PREGNANCY TO 72W POSTPARTUM - (03/10/21)   COVID Virus Can Linger in Gut a Half-Year After Symptoms Clear - Mark Mascolini - (03/10/21)   Disrupted Gut Integrity, Other Gut Factors, Tied to COVID-19 Severity - Mark Mascolini - (03/10/21)   Low New-HIV Rate With Both Daily and On-Demand PrEP in Paris MSM - Mark Mascolini - (03/10/21)   Resistance and Response in Phase 2a Study of HIV Maturation Inhibitor - Mark Mascolini - (03/10/21)   Gilead's Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI - (03/10/21)   Racial/Ethnic Minorities With HIV More Likely to Get COVID-19 in US - Mark Mascolini (03/09/21)   Tight HBV Control Essential to HCC Prevention in People With HIV - Mark Mascolini (03/09/21)   Low New-HIV Rate With Both Daily and On-Demand PrEP in Paris MSM - (03/09/21)   NNRTI MK-8507 Selects V106 Mutations, Active Against Common NNRTI Mutations - Mark Mascolini (03/09/21)   PHASE IIA PROOF-OF-CONCEPT TRIAL OF NEXT-GENERATION MATURATION INHIBITOR GSK3640254 - (03/09/21)   HIV AND COVID-19 INPATIENT OUTCOMES: A MATCHED RETROSPECTIVE MULTICENTRE ANALYSIS - (03/09/21)   In-Hospital COVID-19 Outcomes Not Worse With HIV in 6-Center UK Analysis - Mark Mascolini (03/09/21)   ACTIVITY AND RESISTANCE CHARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR - (03/09/21)   POTENT ANTIVIRAL ACTIVITY OF LENACAPAVIR IN PHASE 2/3 IN HEAVILY ART-EXPERIENCED PWH - (03/09/21)   RESISTANCE PROFILE OF MK-8507, A NOVEL NNRTI SUITABLE FOR WEEKLY ORAL HIV TREATMENT - (03/09/21)   ASSESSMENT OF OBESITY AND METABOLIC PROFILE BY INTEGRASE INHIBITOR USE IN REPRIEVE - (03/09/21)   Resistance Testing Did Not Boost HIV Control Rates in Randomized African Trial - Mark Mascolini - (03/09/21)   DISPARITIES IN TIMELY RECEIPT OF ART PRESCRIPTION IN HIV CARE IN THE US, 2012-2018 - (03/09/21)   Faster Time to Viral Suppression in US South, But Suppression Rates Still Modest - Mark Mascolini (03/09/21)   Time to ART Improves for Blacks, Southerners in US, But Still Lags for Drug Users - Mark Mascolini (03/09/21)   Second-Line DTG Noninferior to DRV/r in African NADIA Trial - Mark Mascolini (03/09/21)   COVID-19 HOSPITALIZATION AMONG PEOPLE WITH HIV OR SOLID ORGAN TRANSPLANT IN THE US - (03/09/21)   REDUCED SUSCEPTIBILITY TO TEMSAVIR IS NOT LINKED TO IBA OR MVC RESISTANCE - (03/09/21)   GSK3640254 IS A NOVEL MATURATION INHIBITOR WITH AN OPTIMIZED VIROLOGY PROFILE - (03/09/21)   ISLATRAVIR PK THRESHOLD & DOSE SELECTION FOR MONTHLY ORAL HIV-1 PrEP - (03/08/21)   NEXT-GENERATION ISLATRAVIR IMPLANTS PROJECTED TO PROVIDE YEARLY HIV PROPHYLAXIS - (03/08/21)   IDENTIFICATION OF UNIQUE PROTEINS PREDICTIVE OF MORTALITY AND MECHANISMS IN HIV - (03/08/21)   BIOLOGICAL PROFILES PREDICT CORONARY ARTERY DISEASE IN PWH AND RISK-MATCHED CONTROLS - (03/08/21)   Short-course alendronate for the prevention of art-associated bone loss Alendronate for 14 Weeks Before and During First ART Wards Off 48-Week Bone Loss - Mark Mascolini (03/08/21)   PREVENTION OF CARDIOVASCULAR DISEASE IN PERSONS WITH AND WITHOUT HIV - (03/08/21)   Control of Lipids and Diabetes-But Not BP-Cuts Cardio Risk With HIV - Mark Mascolini (03/08/21)   12-Year Cognitive Decline is Associated with Lung Disease, Diabetes, and Depression - (03/08/21)   Diabetes, Lung Disease, Depression, Cannabis Tied to 12-Year Cognitive Drop With HIV - (03/08/21)   Avoid CYP, P-gp, UGT Inducers With HIV Capsid Inhibitor Lenacapavir - Mark Mascolini (03/08/21)   CLINICAL EVALUATION OF DRUG INTERACTIONS WITH ORAL LENACAPAVIR AND PROBE DRUGS - (03/08/21)   Multimorbidity in people with HIV using ART in the US: Projections to 2030 - (03/08/21)   Female Sex Modifies Link Between Inflammation and Non-AIDS Vascular Events - Mark Mascolini (03/08/21)   SEX MODIFIES THE ASSOCIATION BETWEEN INFLAMMATION AND VASCULAR EVENTS IN TREATED HIV - (03/08/21)   INTEGRASE INHIBITORS TARGET MITOCHONDRIA IN BROWN ADIPOCYTES DISRUPTING THERMOGENESIS - (03/08/21)   WEIGHT GAIN AMONG PWH WHO SWITCH TO ART-CONTAINING InSTIs OR TAF - (03/08/21)   HIV WITH TRANSMITTED DRUG RESISTANCE IS DURABLY SUPPRESSED BY B/F/TAF AT WEEK 144 - (03/08/21)   ASSESSMENT OF OBESITY AND METABOLIC PROFILE BY INTEGRASE INHIBITOR USE IN REPRIEVE - (03/07/21)   WEIGHT AND LIPID CHANGES IN PHASE 3 CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING TRIALS - (03/07/21)   IMPACT OF REPRODUCTIVE AGING ON IMMUNE FUNCTION IN CISGENDER MEN AND WOMEN WITH HIV - (03/07/21)   WEIGHT GAIN AFTER SWITCHING DIFFERENT INTEGRASE STRAND TRANSFER INHIBITORS (InSTIs) - (03/07/21)   ASSOCIATION BETWEEN NEWER ANTIRETROVIRALS AND INCREASE IN BODY MASS INDEX IN RESPOND - (03/07/21)   COMORBIDITY BURDEN IN PEOPLE LIVING WITH HIV IN THE UNITED STATES - (03/06/21)   HIV DIFFERENTIALLY IMPACTS AGE-RELATED COMORBIDITY BURDEN AMONG US WOMEN AND MEN - (03/06/21)   MODEL-INFORMED DOSE SELECTION FOR ISLATRAVIR/MK-8507 ORAL ONCE-WEEKLY PHASE 2B STUDY - (03/06/21)   WEEK 96 ANALYSIS OF VIRAL BLIPS FROM A PHASE 2B TRIAL OF ISLATRAVIR AND DORAVIRINE - (03/06/21)   4-YEAR OUTCOMES OF B/F/TAF IN TREATMENT-NAIVE ADULTS - (03/06/21)   SWITCHING TO DTG/3TC FDC IS NONINFERIOR TO TBR FOR 96 WEEKS: TANGO SUBGROUP ANALYSES - (03/06/21)   DURABLE EFFICACY OF DTG+3TC IN GEMINI-1&2: YEAR 3 SUBGROUP ANALYSES - (03/06/21)   WEEKLY ORAL TENOFOVIR ALAFENAMIDE PROTECTS MACAQUES FROM VAGINAL SHIV INFECTION - (03/06/21)   LONG-ACTING HIV CAPSID INHIBITOR EFFECTIVE AS PrEP IN A SHIV RHESUS MACAQUE MODEL - (03/06/21)   LONG-ACTING CABOTEGRAVIR+RILPIVIRINE IN OLDER ADULTS: POOLED PHASE 3 WEEK-48 RESULTS - (03/06/21)   CABOTEGRAVIR PPK SIMULATION TO INFORM Q2M STRATEGIES FOLLOWING DOSING INTERRUPTIONS - (03/06/21)   POPPK MODELING OF Q2M IM RPV LA FOR MANAGING DOSING INTERRUPTIONS IN HIV-1 PATIENTS - (03/06/21)   ViiV Healthcare presents data for long-acting cabotegravir and rilpivirine for the treatment of HIV showing continued virologic suppression to 96 weeks - (03/06/21)   ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside pipeline advances at CROI 2021 - (03/02/21)